A Study of ST-1898 for Unresectable or Metastatic Melanoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of ST-1898 for Unresectable or Metastatic Melanoma — Stella

Home/Unresectable or Metastatic Melanoma/

View on ClinicalTrials.gov

Recruiting

Back to Unresectable or Metastatic Melanoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Peking University Cancer Hospital & Institute, Beijing

Key details

Phase

Early testing / Safety & dosing

Sponsor

Beijing Scitech-Mq Pharmaceuticals Limited

Enrollment target

~64 participants

Started

November 2023

Primary completion

December 2026

Age range

18 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.